R.D. Gelber

1.5k total citations
31 papers, 1.0k citations indexed

About

R.D. Gelber is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, R.D. Gelber has authored 31 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 16 papers in Cancer Research and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in R.D. Gelber's work include Breast Cancer Treatment Studies (14 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Treatment and Pharmacology (5 papers). R.D. Gelber is often cited by papers focused on Breast Cancer Treatment Studies (14 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Treatment and Pharmacology (5 papers). R.D. Gelber collaborates with scholars based in Switzerland, Italy and United States. R.D. Gelber's co-authors include Aron Goldhirsch, A. Goldhirsch, Alan S. Coates, M. Castiglione, Harry S. Wieand, Bernard F. Cole, Georgene Schroeder, James E. Krook, Carole Maver and L M Nadler and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

R.D. Gelber

29 papers receiving 950 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R.D. Gelber Switzerland 18 550 403 231 147 144 31 1.0k
F J Cummings United States 20 691 1.3× 300 0.7× 121 0.5× 159 1.1× 44 0.3× 35 1.2k
Francesco Nuzzo Italy 15 710 1.3× 351 0.9× 127 0.5× 355 2.4× 150 1.0× 48 1.2k
J Robert Canada 9 586 1.1× 445 1.1× 105 0.5× 194 1.3× 73 0.5× 16 955
Robert L. DeWitty United States 16 462 0.8× 370 0.9× 164 0.7× 82 0.6× 49 0.3× 36 983
Hans Wildiers Belgium 9 586 1.1× 257 0.6× 106 0.5× 263 1.8× 86 0.6× 33 1.1k
Lissandra Dal Lago Belgium 18 1.2k 2.1× 219 0.5× 352 1.5× 254 1.7× 81 0.6× 54 1.7k
P. Hupperets Netherlands 21 629 1.1× 340 0.8× 132 0.6× 266 1.8× 46 0.3× 40 1.4k
Cynthia Osborne United States 9 1.0k 1.9× 432 1.1× 233 1.0× 282 1.9× 91 0.6× 12 1.5k
Allen S. Melemed United States 20 844 1.5× 396 1.0× 200 0.9× 352 2.4× 70 0.5× 43 1.4k
Joe Costantino United States 2 592 1.1× 687 1.7× 545 2.4× 143 1.0× 42 0.3× 3 1.2k

Countries citing papers authored by R.D. Gelber

Since Specialization
Citations

This map shows the geographic impact of R.D. Gelber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R.D. Gelber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R.D. Gelber more than expected).

Fields of papers citing papers by R.D. Gelber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R.D. Gelber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R.D. Gelber. The network helps show where R.D. Gelber may publish in the future.

Co-authorship network of co-authors of R.D. Gelber

This figure shows the co-authorship network connecting the top 25 collaborators of R.D. Gelber. A scholar is included among the top collaborators of R.D. Gelber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R.D. Gelber. R.D. Gelber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Niman, Samuel M., Marco Ruggeri, Fedro A. Peccatori, et al.. (2025). LBA12 5-year follow-up results from the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial. Annals of Oncology. 36. S1557–S1557.
2.
Demeestere, Isabelle, Samuel M. Niman, AH Partridge, et al.. (2025). 415O Predictive factors of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in the POSITIVE trial. ESMO Open. 10. 104987–104987. 1 indexed citations
3.
Niman, Samuel M., AH Partridge, Marco Ruggeri, et al.. (2024). 1814O Breastfeeding in women with hormone receptor-positive breast cancer who conceived after temporary interruption of endocrine therapy: Results from the POSITIVE trial. Annals of Oncology. 35. S1076–S1076. 3 indexed citations
4.
5.
Pondé, Noam, Larissa A. Korde, Florentine Hilbers, et al.. (2019). SERIOUS ADVERSE EVENTS AMONG OLDER PATIENTS IN THE ALTTO TRIAL. Journal of Geriatric Oncology. 10(6). S14–S15.
6.
7.
Keshaviah, Aparna, Silvia Dellapasqua, Nicole Rotmensz, et al.. (2007). CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Annals of Oncology. 18(4). 701–708. 80 indexed citations
8.
Goldhirsch, Aron, M. Castiglione, R.D. Gelber, et al.. (1997). Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: Results of the International Breast Cancer Study Group (IBCSG) Trial VI. Annals of Oncology. 8(8). 751–756. 25 indexed citations
9.
Gelber, R.D., Aron Goldhirsch, Bernard F. Cole, et al.. (1996). A Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Adjuvant Radiation Therapy and Chemotherapy for Resectable Rectal Cancer. JNCI Journal of the National Cancer Institute. 88(15). 1039–1045. 95 indexed citations
10.
Goldhirsch, Aron & R.D. Gelber. (1996). Endocrine therapies of breast cancer.. PubMed. 23(4). 494–505. 31 indexed citations
11.
Bernhard, Jürg, Alan S. Coates, M. Castiglione, et al.. (1994). Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: Its effect on patient self-estimation. Annals of Oncology. 5(1). 65–74. 22 indexed citations
12.
Gelber, R.D., A. Goldhirsch, & Alan S. Coates. (1993). Adjuvant therapy for breast cancer: understanding the overview. International Breast Cancer Study Group.. Journal of Clinical Oncology. 11(3). 580–585. 20 indexed citations
13.
Gelber, R.D. & Aron Goldhirsch. (1993). From the Overview to the Patient: How To Interpret Meta-analysis Data. Recent results in cancer research. 127. 167–176. 3 indexed citations
14.
Goldhirsch, Aron, R.D. Gelber, & M. Castiglione. (1991). Adjuvant therapy of breast cancer. European Journal of Cancer and Clinical Oncology. 27(3). 389–399. 10 indexed citations
15.
Gelber, R.D., Rebecca Gelman, & Aron Goldhirsch. (1990). A quality-of-life-oriented endpoint for comparing therapies. Maturitas. 12(2). 152–152. 5 indexed citations
16.
Goldhirsch, Aron & R.D. Gelber. (1989). Adjuvant Chemo-Endocrine Therapy or Endocrine Therapy Alone for Postmenopausal Patients: Ludwig Studies III and IV. Recent results in cancer research. 115. 153–162. 14 indexed citations
17.
Pedrazzini, A, et al.. (1986). First repeated bone scan in the observation of patients with operable breast cancer.. Journal of Clinical Oncology. 4(3). 389–394. 26 indexed citations
18.
Goldhirsch, Aron & R.D. Gelber. (1986). Perioperative and Conventionally Timed Chemotherapy in Operable Breast Cancer: The Ludwig Breast Cancer Study V. Recent results in cancer research. 103. 103–112. 3 indexed citations
19.
Bast, Robert C., Paolo de Fabritiis, Jeffrey M. Lipton, et al.. (1985). Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement.. PubMed. 45(2). 499–503. 109 indexed citations
20.
Davis, L. W., R.D. Gelber, Sebastian Krämer, Marvin Zelen, & P. Rubin. (1978). The Radiation Therapy Oncology Group: a progress report.. PubMed. 1(2). 83–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by F J Cummings Breakdown of academic impact, for papers by Francesco Nuzzo Breakdown of academic impact, for papers by J Robert Breakdown of academic impact, for papers by Robert L. DeWitty Breakdown of academic impact, for papers by Hans Wildiers Breakdown of academic impact, for papers by Lissandra Dal Lago Breakdown of academic impact, for papers by P. Hupperets Breakdown of academic impact, for papers by Cynthia Osborne Breakdown of academic impact, for papers by Allen S. Melemed Breakdown of academic impact, for papers by Joe Costantino
Rankless by CCL
2026